VCEL logo

VERICEL CORP

VCELNASDAQ
๐Ÿ† #1809 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track VCEL
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$2.06B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
25.3%
High Growth
๐Ÿ“ŠGross Margin
74.5%
High
๐Ÿ’ตFCF Margin
17.9%
Healthy
โš–๏ธP/S Ratio
9.2x
Elevated
Otter Score
โ€”
Insufficient data
No chart data available for VCEL.

Trading Snapshot

Day Range
โ€”
52-Week Range
$28.95 โ€“ $59.75
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
51.2M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$276M
Last Q Revenue
$85M
P/E Ratio
89.2
P/S Ratio
9.2x
EPS (TTM)
$0.59
Dividend Yield
โ€”
VCEL logo

VERICEL CORP

VCEL
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About VERICEL CORP

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.